CA3201758A1 - Mof nanoparticles - Google Patents

Mof nanoparticles

Info

Publication number
CA3201758A1
CA3201758A1 CA3201758A CA3201758A CA3201758A1 CA 3201758 A1 CA3201758 A1 CA 3201758A1 CA 3201758 A CA3201758 A CA 3201758A CA 3201758 A CA3201758 A CA 3201758A CA 3201758 A1 CA3201758 A1 CA 3201758A1
Authority
CA
Canada
Prior art keywords
polymer
mof
nanoparticles
coated
pcn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201758A
Other languages
English (en)
French (fr)
Inventor
David Fairen Jimenez
Xu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CA3201758A1 publication Critical patent/CA3201758A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CA3201758A 2020-12-09 2021-12-09 Mof nanoparticles Pending CA3201758A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20212892.2 2020-12-09
EP20212892.2A EP4011365A1 (en) 2020-12-09 2020-12-09 Mof nanoparticles
PCT/EP2021/085108 WO2022122983A1 (en) 2020-12-09 2021-12-09 Mof nanoparticles

Publications (1)

Publication Number Publication Date
CA3201758A1 true CA3201758A1 (en) 2022-06-16

Family

ID=73790017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201758A Pending CA3201758A1 (en) 2020-12-09 2021-12-09 Mof nanoparticles

Country Status (6)

Country Link
US (1) US20240050379A1 (https=)
EP (2) EP4011365A1 (https=)
JP (1) JP2024500350A (https=)
AU (1) AU2021395441A1 (https=)
CA (1) CA3201758A1 (https=)
WO (1) WO2022122983A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115505131B (zh) * 2022-09-19 2023-07-11 西南交通大学 氨基功能化的发光金属有机骨架及其制备方法和应用
CN115895152B (zh) * 2022-09-19 2023-12-26 西南交通大学 pH膜传感器、pH膜传感器的制备方法以及pH值的检测方法
CN116036263B (zh) * 2022-12-20 2026-01-13 西南大学 一种基于锆金属有机框架的复合纳米佐剂制剂及其在动物疫苗中的应用
WO2025010407A2 (en) * 2023-07-05 2025-01-09 The University Of Chicago Nanoscale metal-organic frameworks with x-ray triggerable prodrugs for combination radiotherapy, chemotherapy, and immunotherapy
WO2025125382A1 (en) 2023-12-11 2025-06-19 Cambridge Enterprise Limited Mof nanoparticles
WO2025125384A1 (en) 2023-12-11 2025-06-19 Cambridge Enterprise Limited Hydrogel compositions
CN119896750B (zh) * 2025-01-23 2025-11-04 常州大学 一种负载侧柏精油的钾掺杂金属有机骨架抗菌纳米粒及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921661B1 (fr) * 2007-10-01 2013-05-31 Centre Nat Rech Scient Solide hybride organique inorganique a surface modifiee.
GB2472446A (en) * 2009-08-07 2011-02-09 Ct Fuer Angewandte Nanotechnologie Metal oxide particles coated with polyethylene glycol and their synthesis
CN110731961A (zh) * 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
GB201511125D0 (en) 2015-06-24 2015-08-05 Cambridge Entpr Ltd Amorhous metal-organic frameworks
MX2020000387A (es) * 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.

Also Published As

Publication number Publication date
JP2024500350A (ja) 2024-01-09
AU2021395441A9 (en) 2023-07-27
EP4011365A1 (en) 2022-06-15
EP4259109A1 (en) 2023-10-18
US20240050379A1 (en) 2024-02-15
WO2022122983A1 (en) 2022-06-16
AU2021395441A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20240050379A1 (en) Mof nanoparticles
Chen et al. Formulation of metal–organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility
Javanbakht et al. Incorporating Cu-based metal-organic framework/drug nanohybrids into gelatin microsphere for ibuprofen oral delivery
Jafari et al. Highly efficient sunitinib release from pH-responsive mHPMC@ Chitosan core-shell nanoparticles
KR101993297B1 (ko) 변형된 외부 표면을 가진 개선된 유기-무기 하이브리드 고체
Tang et al. Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery
Yang et al. Synthesis and characterization of biotin modified cholesteryl pullulan as a novel anticancer drug carrier
Zhao et al. PEGylated mesoporous silica as a redox-responsive drug delivery system for loading thiol-containing drugs
Gil et al. Injectable hydrogel-incorporated cancer cell-specific cisplatin releasing nanogels for targeted drug delivery
Phan et al. Pancreatic cancer therapy using an injectable nanobiohybrid hydrogel
US10272157B2 (en) Porous solid with outer surface grafted with a polymer
Pongjanyakul et al. Enhanced entrapment efficiency and modulated drug release of alginate beads loaded with drug–clay intercalated complexes as microreservoirs
Kong et al. Polyethyleneimine-stabilized hydroxyapatite nanoparticles modified with hyaluronic acid for targeted drug delivery
Fazio et al. Laser light triggered smart release of silibinin from a PEGylated–PLGA gold nanocomposite
SG173455A1 (en) Hollow silica particle with a polymer thereon
Liu et al. Enhancing drug delivery efficacy through bilayer coating of zirconium-based metal–organic frameworks: sustained release and improved chemical stability and cellular uptake for cancer therapy
CN101058649A (zh) 一种稳定的具有核－壳结构的纳米凝胶及其制备方法和应用
Yang et al. Multifunctional mesoporous silica nanoparticles with different morphological characteristics for in vitro cancer treatment
Yan et al. Templated fabrication of pH-responsive poly (l-glutamic acid) based nanogels via surface-grafting and macromolecular crosslinking
Khoee et al. Preparation of dual-targeted redox-responsive nanogels based on pegylated sorbitan for targeted and antitumor drug delivery
de Oliveira et al. Reduced cytotoxicity of nanomaterials driven by nano-bio interactions: Case study of single protein coronas enveloping polymersomes
Bedoya et al. Risedronate functionalized layered double hydroxides nanoparticles with bone targeting capabilities
Chen et al. Preparation and biological evaluation of antibody targeted metal-organic framework drug delivery system (TDDS) in Her2 receptor-positive cells
García-Uriostegui et al. Synthesis and characterization of mesoporous silica-g-poly (hydroxyethylmethacrylate) nanohybrid particles as a drug delivery system
Duan et al. Characterization and performance evaluation of pH-sensitive drug delivery of mesoporous silica with honeycomb structure for treatment of cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241029

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241029

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241029

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251106

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20251127

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251127

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20260108

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260122

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260122

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260122